Impairment in work and activities of daily life in patients with psoriasis: results of the prospective BioCAPTURE registry

References

• Augustin M, Radtke MA. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Res. 2014;14(4):1–9. doi: 10.1586/14737167.2014.914437.
   PubMed Web of Science ®Google Scholar
• Raval K, Lofland JH, Waters H, et al. Disease and treatment burden of psoriasis: examining the impact of biologics. J Drugs Dermatol. 2011;10(2):189–196.
   PubMed Web of Science ®Google Scholar
• Sumpton D, Kelly A, Tunnicliffe DJ, et al. Patients’ perspectives and experience of psoriasis and psoriatic arthritis: a systematic review and thematic synthesis of qualitative studies. Arthritis Care Res (Hoboken). 2020;72(5):711–722.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Schupp C, Wu J, et al. Quality of life and work productivity impairment among psoriasis patients: findings from the national psoriasis foundation survey data 2003-2011. PLoS One. 2012;7(12):e52935. doi: 10.1371/journal.pone.0052935.
   PubMed Web of Science ®Google Scholar
• Rasmussen MK, Enger M, Dahlborn AK, et al. The importance of achieving clear or almost clear skin for patients: results from the nordic countries of the global. Acta Derm Venereol. 2019;99(2):158–163. doi: 10.2340/00015555-3048.
   PubMed Web of Science ®Google Scholar
• Orbai AM, Reddy SM, Dennis N, et al. Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-A retrospective study of claims data from 2009 TO 2020. Clin Rheumatol. 2021;40(12):4933–4942. doi: 10.1007/s10067-021-05839-9.
   PubMed Web of Science ®Google Scholar
• Strober B, Greenberg JD, Karki C, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the corrona psoriasis registry. BMJ Open. 2019;9(4):e027535. doi: 10.1136/bmjopen-2018-027535.
   PubMed Web of Science ®Google Scholar
• Claudepierre P, Lahfa M, Levy P, et al. The impact of psoriasis on professional life: PsoPRO, a French national survey. J Eur Acad Dermatol Venereol. 2018;32(10):1702–1709. doi: 10.1111/jdv.14986.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Soliman AM, Yang H, et al. Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis. J Dermatolog Treat. 2022;33(4):2094–2101.
   PubMed Web of Science ®Google Scholar
• Reich K, Foley P, Han C, et al. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. J Dermatolog Treat. 2020;31(6):617–623. doi: 10.1080/09546634.2019.1628172.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Lin C, Sun L, et al. Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patients. J Eur Acad Dermatol Venereol. 2019;33(2):318–324. doi: 10.1111/jdv.15098.
   PubMed Web of Science ®Google Scholar
• Kouwenhoven TA, van der Ploeg JAM, van de Kerkhof PCM. Treatment goals in psoriasis from a patient perspective: a qualitative study. J Dermatolog Treat. 2020;31(1):13–17. doi: 10.1080/09546634.2018.1544408.
   PubMed Web of Science ®Google Scholar
• Wolf P, Weger W, Legat F, et al. Quality of life and treatment goals in psoriasis from the patient perspective: results of an Austrian cross-sectional survey. J Dtsch Dermatol Ges. 2018;16(8):981–990. doi: 10.1111/ddg.13613.
   Web of Science ®Google Scholar
• Saeki H, Kanai Y, Murotani K, et al. Work productivity in real-life employed patients with plaque psoriasis: results from the ProLOGUE study. J Dermatol. 2022;49(10):970–978. doi: 10.1111/1346-8138.16517.
   PubMed Web of Science ®Google Scholar
• Beroukhim K, Danesh M, Nguyen C, et al. A prospective, interventional assessment of the impact of ustekinumab treatment on psoriasis-related work productivity and activity impairment. J Dermatolog Treat. 2016;27(6):552–555. doi: 10.3109/09546634.2016.1165339.
   PubMed Web of Science ®Google Scholar
• Warren RB, Halliday A, Graham CN, et al. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. J Eur Acad Dermatol Venereol. 2018;32(12):2178–2184. doi: 10.1111/jdv.15094.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Zhao Y, Gilloteau I, et al. Higher psoriasis skin clearance is associated with lower annual indirect costs in the United States: a post hoc analysis from the CLEAR study. J Manag Care Spec Pharm. 2018;24(7):617–622. doi: 10.18553/jmcp.2018.24.7.617.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Lynde CW, McBride SR, et al. Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase 3 clinical trials. JAMA Dermatol. 2016;152(6):661–669. doi: 10.1001/jamadermatol.2016.0269.
   PubMed Web of Science ®Google Scholar
• Revicki D, Willian MK, Saurat JH, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2008;158(3):549–557. doi: 10.1111/j.1365-2133.2007.08236.x.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Yu AP, Signorovitch J, et al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;66(2):e67-76–e76. doi: 10.1016/j.jaad.2010.10.020.
   PubMedGoogle Scholar
• Papp KA, Sundaram M, Bao Y, et al. Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. J Eur Acad Dermatol Venereol. 2014;28(6):790–798. doi: 10.1111/jdv.12177.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8.
   PubMedGoogle Scholar
• Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244. doi: 10.1159/000250839.
   PubMedGoogle Scholar
• Finlay AY, Khan GK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x.
   PubMed Web of Science ®Google Scholar
• Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483. doi: 10.1097/00005650-199206000-00002.
   PubMed Web of Science ®Google Scholar
• Koopmanschap MA. PRODISQ: a modular questionnaire on productivity and disease for economic evaluation studies. Expert Rev Pharmacoecon Outcomes Res. 2005;5(1):23–28. doi: 10.1586/14737167.5.1.23.
   PubMedGoogle Scholar
• Bouwmans C, De Jong K, Timman R, et al. Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P). BMC Health Serv Res. 2013;13(1):217. doi: 10.1186/1472-6963-13-217.
   PubMedGoogle Scholar
• Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44(4):1049–1060. doi: 10.2307/2531734.
   PubMed Web of Science ®Google Scholar
• Statistiek CBvd. De arbeidsmarkt in cijfers 2019. In: statistiek CBvd, editor. Den Haag/Heerlen/Bonaire; 2020.
   Google Scholar
• van Hal TW, Mulder MLM, Wenink MH, et al. Determinants of work and social participation in patients with psoriatic arthritis in The Netherlands: an observational study. BMC Rheumatol. 2022;6(1):49. doi: 10.1186/s41927-022-00279-7.
   PubMedGoogle Scholar
• Wervers K, Luime JJ, Tchetverikov I, et al. Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritis. Arthritis Res Ther. 2019;21(1):25. doi: 10.1186/s13075-019-1811-4.
   PubMedGoogle Scholar
• Villacorta R, Teeple A, Lee S, et al. A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis. Br J Dermatol. 2020;183(3):548–558. doi: 10.1111/bjd.18798.
   PubMed Web of Science ®Google Scholar
• Bronckers I, van Geel MJ, van de Kerkhof PCM, et al. A cross-sectional study in young adults with psoriasis: potential determining factors in quality of life, life course and work productivity. J Dermatolog Treat. 2019;30(3):208–215. doi: 10.1080/09546634.2018.1506077.
   PubMed Web of Science ®Google Scholar
• Schaefer CP, Cappelleri JC, Cheng R, et al. Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. J Am Acad Dermatol. 2015;73(4):585–593 e3. doi: 10.1016/j.jaad.2015.06.049.
   PubMed Web of Science ®Google Scholar
• Chan B, Hales B, Shear N, et al. Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis. J Cutan Med Surg. 2009;13(4):192–197. doi: 10.2310/7750.2009.08068.
   PubMed Web of Science ®Google Scholar
• Vender R, Lynde C, Ho V, et al. Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: results from a 1-year, multicentre, open-label, single-arm study in a clinical setting. Appl Health Econ Health Policy. 2012;10(5):343–353. doi: 10.1007/BF03261868.
   PubMedGoogle Scholar
• Kimball AB, Luger T, Gottlieb A, et al. Long-term impact of ixekizumab on psoriasis itch severity: results from a phase III clinical trial and long-term extension. Acta Derm Venereol. 2018;98(1):98–102. doi: 10.2340/00015555-2801.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Saeki H, Ito T, et al. Impact of disease severity on work productivity and activity impairment in Japanese patients with psoriasis. J Dermatol Sci. 2013;72(2):188–191. doi: 10.1016/j.jdermsci.2013.06.003.
   PubMed Web of Science ®Google Scholar
• Korman NJ, Zhao Y, Pike J, et al. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol. 2016;41(5):514–521. doi: 10.1111/ced.12841.
   PubMed Web of Science ®Google Scholar
• Strober B, Patil D, McLean RR, et al. Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting. J Dermatolog Treat. 2022;33(8):3178–3187.
   PubMed Web of Science ®Google Scholar
• Lewis-Beck C, Abouzaid S, Xie L, et al. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence. 2013;7:199–205. doi: 10.2147/PPA.S39887.
   PubMed Web of Science ®Google Scholar